Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France

SUMMARY: The use of gastro-resistant risedronate, a convenient dosing regimen for oral bisphosphonate therapy, seems a cost-effective strategy compared with weekly alendronate, generic risedronate, and no treatment for the treatment of postmenopausal women with osteoporosis in France. INTRODUCTION:...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiligsmann, M., Reginster, J.-Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423313/
https://www.ncbi.nlm.nih.gov/pubmed/30701342
http://dx.doi.org/10.1007/s00198-018-04821-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423313/
https://www.ncbi.nlm.nih.gov/pubmed/30701342
http://dx.doi.org/10.1007/s00198-018-04821-7

Ejemplares similares